杭州浙大迪迅生物基因工程有限公司Release date：2019-12-23
JACI
https://doi.org/10.1016/j.jaip.2012.11.002
Background
Increasing data suggest that analysis of IgE to peanut components can be clinically helpful and possibly more accurate than IgE to whole peanut. Not all studies examining this topic, however, have used prospective samples, multiple components, and peanut challenges.
Objective
We sought to determine the utility of peanut component testing, using a standardized, commercially available test done before oral peanut challenge in various populations of patients with suspected peanut allergy from 2 different countries.
Methods
IgE to whole peanut and the recombinant allergen components Ara h 1, 2, 3, and 8 were analyzed from serum samples drawn before double-blind peanut challenge from 4 distinct cohorts of patients with suspected peanut allergy from 2 nations (United States and Sweden).
Results
Patients (n = 167; median age, 11.7 years; interquartile range, 7.0-15.0 years) had serum analyzed for peanut components and completed an oral food challenge to peanut. Although IgE to peanut was the most sensitive test (0.93), Ara h 2 was the most specific (0.92) and provided the best positive predictive value (0.94) of all the tests. Ara h 2 was also the best overall diagnostic test by receiver operating characteristic analysis (area under the curve, 0.84; P < .05).
Conclusions
In patients with suspected peanut allergy, IgE to peanut is a sensitive test but is not specific. IgE to Ara h 2 is a more specific and more accurate diagnostic test in this sampling of patients with suspected peanut allergy. Given each tests attributes, a stepwise approach to testing may provide clinicians with a way to minimize the need for peanut challenges.
All Author:
A.LiebermanMDa∗SusanneGlaumannMDbcSofiaBatelsonMDcMagnus P.BorresMD, PhDdeHugh A.SampsonMDaCarolineNilssonMD, PhDbc
[IF:13.1]
The Utility of Peanut Components in the Diagnosis of IgE-Mediated Peanut Allergy Among Distinct Populationshttps://doi.org/10.1016/j.jaip.2012.11.002
Background
Increasing data suggest that analysis of IgE to peanut components can be clinically helpful and possibly more accurate than IgE to whole peanut. Not all studies examining this topic, however, have used prospective samples, multiple components, and peanut challenges.
Objective
We sought to determine the utility of peanut component testing, using a standardized, commercially available test done before oral peanut challenge in various populations of patients with suspected peanut allergy from 2 different countries.
Methods
IgE to whole peanut and the recombinant allergen components Ara h 1, 2, 3, and 8 were analyzed from serum samples drawn before double-blind peanut challenge from 4 distinct cohorts of patients with suspected peanut allergy from 2 nations (United States and Sweden).
Results
Patients (n = 167; median age, 11.7 years; interquartile range, 7.0-15.0 years) had serum analyzed for peanut components and completed an oral food challenge to peanut. Although IgE to peanut was the most sensitive test (0.93), Ara h 2 was the most specific (0.92) and provided the best positive predictive value (0.94) of all the tests. Ara h 2 was also the best overall diagnostic test by receiver operating characteristic analysis (area under the curve, 0.84; P < .05).
Conclusions
In patients with suspected peanut allergy, IgE to peanut is a sensitive test but is not specific. IgE to Ara h 2 is a more specific and more accurate diagnostic test in this sampling of patients with suspected peanut allergy. Given each tests attributes, a stepwise approach to testing may provide clinicians with a way to minimize the need for peanut challenges.
All Author:
A.LiebermanMDa∗SusanneGlaumannMDbcSofiaBatelsonMDcMagnus P.BorresMD, PhDdeHugh A.SampsonMDaCarolineNilssonMD, PhDbc
2019-11- 15 Article
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd. Copyright HZKC Technical support 浙ICP备14005341号 （浙）-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist. Tel: 0571-87968248-805 Website:www.zdbiogene.com
COPYRIGHT©2003-2024 www.zdbiogene.com CORPORATION. ALL RIGHTS RESERVED
Official WeChat